Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-06-18FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for trazodone hydrochloride from Torrent Pharmaceuticals Limited, bringing the generic product into …
-
FDA approval · 2025-06-16FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved a supplemental application for trazodone hydrochloride submitted by Accord Healthcare, Inc. The action confirms the continued r…
-
FDA approval · 2025-05-23FDA Approved: BUPROPION HYDROCHLORIDE XL — Supplemental Application (Slate Run Pharmaceuticals, LLC)
The FDA approved a supplemental application for Bupropion hydrochloride XL from Slate Run Pharmaceuticals, approving the extended-release fo…
-
FDA approval · 2025-05-15FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)
The FDA approved a supplemental application for Spravato (esketamine hydrochloride) submitted by Janssen Pharmaceuticals. The action updates…
-
FDA approval · 2025-05-08FDA Approved: MIRTAZAPINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for mirtazapine by Aurobindo Pharma Limited under ANDA077376.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-04-28FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)
FDA approves a supplemental application for SPRAVATO (esketamine hydrochloride) submitted by Janssen Pharmaceuticals Inc.
-
FDA approval · 2025-04-23FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for venlafaxine hydrochloride submitted by Macleods Pharmaceuticals Limited.
-
FDA approval · 2025-04-18FDA Approved: BUPROPION HYDROCHLORIDE SR — Supplemental Application (Dr. Reddys Laboratories Inc.)
FDA approved a supplemental application for Bupropion Hydrochloride SR from Dr. Reddy's Laboratories, authorizing its continued marketing as…
-
EMA approval · 2025-04-15EMA Authorised: Valdoxan (agomelatine) — Les Laboratoires Servier
The EMA authorised Valdoxan (agomelatine) for major depressive disorder, with Les Laboratoires Servier as the marketing authorisation holder…
-
FDA approval · 2025-03-28FDA Approved: DULOXETINE DELAYED-RELEASE — Supplemental Application (Breckenridge Pharmaceutical, Inc.)
The FDA approved Breckenridge Pharmaceutical's supplemental ANDA for a duloxetine hydrochloride delayed-release product, making a generic du…
-
FDA approval · 2025-03-24FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)
FDA approved Janssen's supplemental application for SPRAVATO (esketamine hydrochloride) under NDA 211243, updating the product's indications…
-
FDA approval · 2025-03-24FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for Bupropion Hydrochloride (generic) from Amneal Pharmaceuticals of New York LLC.
-
FDA approval · 2025-03-18FDA Approved: ZIPRASIDONE HYDROCHLORIDE — Supplemental Application (BluePoint Laboratories)
FDA approves BluePoint Laboratories' supplemental application for ZIPRASIDONE HYDROCHLORIDE, a generic form of ziprasidone, indicating appro…
-
FDA approval · 2025-03-14FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for bupropion hydrochloride from Micro Labs Limited.
-
FDA approval · 2025-03-13FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA granted approval of a supplemental application for bupropion hydrochloride from Aurobindo Pharma Limited.
-
FDA approval · 2025-03-13FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
The FDA approved a supplemental application for paroxetine hydrochloride (paroxetine) as a generic product under NorthStar Rx LLC's ANDA.
-
FDA approval · 2025-03-06FDA Approved: BUPROPION — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved Zydus Pharmaceuticals USA Inc.'s supplemental application for Bupropion (ANDA 201567), enabling a generic version of the antide…
-
FDA approval · 2025-03-05FDA Approved: ESCITALOPRAM — Supplemental Application (SOLCO HEALTHCARE US, LLC)
The FDA granted a supplemental approval for escitalopram (generic) from Solco Healthcare US, LLC under an ANDA.
-
FDA approval · 2025-02-28FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride from Zydus Lifesciences Limited, adding regulatory approval for this ge…
-
FDA approval · 2025-02-18FDA Approved: ARIPIPRAZOLE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application from Bionpharma Inc. for aripiprazole (generic), enabling its continued commercialization with the a…
-
FDA approval · 2025-02-15FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (XLCare Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Sertraline Hydrochloride from XLCare Pharmaceuticals, Inc., authorizing the generic product.
-
FDA approval · 2025-02-14FDA Approved: ARIPIPRAZOLE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for aripiprazole from Bionpharma Inc., enabling the generic product to be marketed in the United Sta…
-
FDA approval · 2025-02-11FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for paroxetine (Padagis US LLC), updating the labeling to reflect expanded indications for the antid…
-
FDA approval · 2025-02-11FDA Approved: BUPROPION HYDROCHLORIDE XL — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved a supplemental application to authorize Lupin Pharmaceuticals' generic Bupropion Hydrochloride XL.
-
FDA approval · 2025-01-29FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Teva Pharmaceuticals USA's olanzapine and fluoxetine combination product.